Recent studies have shown that lhcgr is expressed at high levels in various gynaecological cancers and so it was predicted be a potentially important biomarker for cancer diagnosis and therapy, in particular for ovarian cancer (Xiong et al., 2019; Zhong et al., 2019). This evidence concerns the gene LHCGR and ovarian carcinoma.